{"id":"tiv","safety":{"commonSideEffects":[{"rate":"10-64","effect":"Injection site soreness"},{"rate":"5-35","effect":"Myalgia"},{"rate":"5-35","effect":"Headache"},{"rate":"5-20","effect":"Fatigue"},{"rate":"5-15","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL3039529","moleculeType":"Small molecule","molecularWeight":"230.27"},"_dailymed":{"setId":"ced9a8b6-ef2c-a620-c61c-ff9374249543","title":"FLUZONE TIV SH 2026 (INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/SINGAPORE/GP20238/2024 IVR-277 (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), AND INFLUENZA B VIRUS B/MICHIGAN/01/2021 ANTIGEN (FORMALDEHYDE INACTIVATED)) INJECTION, SUSPENSION [SANOFI VACCINES US INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TIV contains inactivated (killed) virus particles from three influenza strains (typically two A strains and one B strain) that trigger both humoral and cellular immune responses. The vaccine prepares the immune system to recognize and neutralize circulating influenza viruses, reducing infection risk and severity. Annual reformulation addresses evolving circulating strains.","oneSentence":"TIV is a trivalent inactivated influenza vaccine that stimulates immune response against three strains of influenza virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:53.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT06417853","phase":"PHASE1","title":"Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)","status":"COMPLETED","sponsor":"Vaxxas Pty Ltd","startDate":"2024-07-31","conditions":"H7N9 Influenza","enrollment":267},{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT07371650","phase":"PHASE2","title":"This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Traws Pharma, Inc.","startDate":"2025-12-15","conditions":"Influenza","enrollment":105},{"nctId":"NCT07496736","phase":"PHASE3","title":"Post-exposure Influenza Prophylaxis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Centre Ljubljana","startDate":"2025-12-01","conditions":"Influenza","enrollment":200},{"nctId":"NCT04304768","phase":"PHASE4","title":"Opioid, HIV and Immune System","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-11-18","conditions":"Immune Defect","enrollment":400},{"nctId":"NCT01386424","phase":"","title":"Screening for LID Clinical Studies Unit Healthy Volunteer Protocols","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-20","conditions":"Zika, Influenza","enrollment":5000},{"nctId":"NCT02511002","phase":"","title":"Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-07-17","conditions":"Post Influenza","enrollment":200},{"nctId":"NCT05332899","phase":"PHASE1","title":"Influenza Human Challenge Model","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-05-24","conditions":"Influenza","enrollment":80},{"nctId":"NCT07204964","phase":"PHASE2","title":"A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-10-07","conditions":"Influenza, Human","enrollment":971},{"nctId":"NCT07215871","phase":"PHASE1","title":"Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza Infection, Infections, Respiratory Virus Infections","enrollment":33},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT07493460","phase":"PHASE4","title":"Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-08-26","conditions":"Immunology, Healthy Adults","enrollment":25},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT04367883","phase":"","title":"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection","status":"RECRUITING","sponsor":"Consorci Sanitari de Terrassa","startDate":"2020-03-01","conditions":"COVID19, Influenza Vaccination, ACE Inhibitors","enrollment":3000},{"nctId":"NCT07300085","phase":"PHASE1","title":"A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-11-08","conditions":"Healthy Participants","enrollment":100},{"nctId":"NCT01191853","phase":"","title":"Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2009-09-18","conditions":"Healthy Volunteers, Influenza","enrollment":203},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT07236814","phase":"PHASE3","title":"Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-11-28","conditions":"Influenza","enrollment":384},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT07431853","phase":"PHASE2","title":"A Study to Learn About mRNA Vaccines Against Influenza in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-23","conditions":"Healthy Adults","enrollment":770},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT07169318","phase":"PHASE1","title":"First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-16","conditions":"Influenza","enrollment":78},{"nctId":"NCT04743609","phase":"NA","title":"RSV Burden in Outpatient and Hospital Settings","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2021-02-08","conditions":"RSV Infection, Children, Only, Outpatient","enrollment":1900},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07340047","phase":"PHASE1","title":"H1ssF Flu Vaccine Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-08-01","conditions":"Influenza","enrollment":112},{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":"Preventable Disease, Vaccine","enrollment":600},{"nctId":"NCT06689423","phase":"","title":"Clinical Evaluation of the VitaSIRO Solo™ Respiratory Assay","status":"COMPLETED","sponsor":"Credo Diagnostics Biomedical Pte. Ltd.","startDate":"2024-11-01","conditions":"SARS-CoV-2, COVID-19, RSV","enrollment":1268},{"nctId":"NCT04579588","phase":"","title":"Understanding Immunity to the Flu Vaccine in COVID-19 Patients","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Corona Virus Infection, Flu Vaccine, Immunity","enrollment":230},{"nctId":"NCT02140047","phase":"PHASE2","title":"Exploratory Clinical Study of MT-2301","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2014-04","conditions":"Haemophilus Influenza Type b","enrollment":154},{"nctId":"NCT05705440","phase":"PHASE3","title":"A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-02-07","conditions":"Respiratory Syncytial Virus Infections","enrollment":3855},{"nctId":"NCT02200276","phase":"NA","title":"Influenza Immunization in Adults Over Age 75","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2014-03","conditions":"Influenza, Immunization, Older Adults","enrollment":1025},{"nctId":"NCT01804634","phase":"PHASE2","title":"Reduced Intensity Haploidentical BMT for High Risk Solid Tumors","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-03-27","conditions":"Refractory and/or Relapsed Metastatic Solid Tumors","enrollment":60},{"nctId":"NCT07110532","phase":"PHASE1","title":"pH1N1 Blinded Challenge Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Influenza","enrollment":180},{"nctId":"NCT07291635","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine","status":"RECRUITING","sponsor":"Aramis Biotechnologies Inc.","startDate":"2026-02-25","conditions":"Influenza","enrollment":728},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT07431840","phase":"NA","title":"Immune Defense Protein Impact On Respiratory Immune Outcomes","status":"RECRUITING","sponsor":"Quantec Ltd","startDate":"2025-12-05","conditions":"Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection","enrollment":300},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT07393685","phase":"","title":"Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University","startDate":"2026-08-01","conditions":"Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Influenza, Human, Virus Diseases","enrollment":300},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT07460154","phase":"NA","title":"Structured Review: To Optimise Management and Prevent Harm in COPD","status":"NOT_YET_RECRUITING","sponsor":"Northumbria Healthcare NHS Foundation Trust","startDate":"2026-03-01","conditions":"COPD","enrollment":96},{"nctId":"NCT06599658","phase":"PHASE2","title":"COVID-19 Booster and IIV Schedule in Immunocompromised Hosts","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2024-11-20","conditions":"COVID 19, Influenza, Rheumatoid Arthritis (RA)","enrollment":660},{"nctId":"NCT05446740","phase":"PHASE1","title":"A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-08-09","conditions":"Influenza, Human","enrollment":324},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06094010","phase":"PHASE3","title":"A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-22","conditions":"Influenza","enrollment":750},{"nctId":"NCT06800885","phase":"","title":"Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-10-22","conditions":"Influenza Immunization","enrollment":5000},{"nctId":"NCT07238114","phase":"","title":"Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-08-01","conditions":"Liver Cirrhosis, Viral Pneumonia, Fungal Infection","enrollment":450},{"nctId":"NCT06753474","phase":"PHASE1","title":"A/Texas Flu Challenge","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-02-04","conditions":"Influenza","enrollment":50},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT06336317","phase":"PHASE4","title":"Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","status":"RECRUITING","sponsor":"Region Örebro County","startDate":"2024-04-24","conditions":"Acute Myocardial Infarction, Cardiovascular Diseases, Inflammatory Response","enrollment":90},{"nctId":"NCT07430410","phase":"NA","title":"Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test","status":"NOT_YET_RECRUITING","sponsor":"CorDx, Inc.","startDate":"2026-02-12","conditions":"SARS-CoV-2 Infection, Influenza A, Influenza B","enrollment":200},{"nctId":"NCT06676644","phase":"NA","title":"Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-11-21","conditions":"Influenza Vaccines, Elderly","enrollment":200},{"nctId":"NCT04901455","phase":"EARLY_PHASE1","title":"Responses to Live Attenuated Influenza Virus (LAIV) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-03","conditions":"COPD","enrollment":24},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT07159763","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cidara Therapeutics Inc.","startDate":"2025-09-25","conditions":"Influenza","enrollment":7500},{"nctId":"NCT06863142","phase":"PHASE1","title":"Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-28","conditions":"Influenza Prevention, Seasonal Influenza","enrollment":45},{"nctId":"NCT05864118","phase":"NA","title":"Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2023-08-21","conditions":"Respiratory Tract Infections","enrollment":1000},{"nctId":"NCT04164212","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-09-01","conditions":"Influenza","enrollment":33},{"nctId":"NCT05648448","phase":"PHASE2","title":"A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2023-02-22","conditions":"Influenza, Influenza, Human","enrollment":3000},{"nctId":"NCT07421050","phase":"PHASE1","title":"Clinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07421037","phase":"PHASE1","title":"Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07420985","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.","status":"RECRUITING","sponsor":"Valenta Pharm JSC","startDate":"2025-10-24","conditions":"Influenza, Acute Respiratory Viral Infection","enrollment":300},{"nctId":"NCT05202379","phase":"PHASE1","title":"CC-42344 Safety Study in Healthy Participants","status":"COMPLETED","sponsor":"Cocrystal Pharma, Inc.","startDate":"2022-02-11","conditions":"Influenza A","enrollment":80},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT07403019","phase":"","title":"Burden of Respiratory Viruses in India.","status":"NOT_YET_RECRUITING","sponsor":"MAHAN Trust","startDate":"2026-04-01","conditions":"Pneumonia","enrollment":2000},{"nctId":"NCT07171099","phase":"PHASE3","title":"Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children","status":"RECRUITING","sponsor":"Materia Medica Holding","startDate":"2025-10-03","conditions":"Cough","enrollment":264},{"nctId":"NCT06567860","phase":"PHASE4","title":"Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations","status":"COMPLETED","sponsor":"La Jolla Institute for Immunology","startDate":"2024-05-21","conditions":"Influenza A","enrollment":23},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT04712539","phase":"PHASE2","title":"Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-11","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Influenza","enrollment":60},{"nctId":"NCT07161739","phase":"NA","title":"Vaccination Nudges From Pharmacists","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2025-11-06","conditions":"Stroke, Influenza Human, Influenza Vaccines","enrollment":20000},{"nctId":"NCT06160128","phase":"","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-09-26","conditions":"COVID-19, SARS-CoV-2 Infection, RSV, Influenza","enrollment":400000},{"nctId":"NCT07282795","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-03-31","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":670},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT06807840","phase":"","title":"Flu Infection at UPHS","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-01-27","conditions":"Influenza Human","enrollment":50},{"nctId":"NCT07386912","phase":"","title":"Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","status":"NOT_YET_RECRUITING","sponsor":"Research Center Borstel","startDate":"2026-02-01","conditions":"Asthma, COPD, Bacterial Pneumonia","enrollment":100},{"nctId":"NCT07386509","phase":"EARLY_PHASE1","title":"WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues.","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2020-03-17","conditions":"Healthy","enrollment":2},{"nctId":"NCT07019883","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-06-12","conditions":"Avian Influenza","enrollment":80},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT07372950","phase":"NA","title":"Kaiser Colorado Flu Nudge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kaiser Permanente","startDate":"2025-10-06","conditions":"Influenza, Vaccination","enrollment":100000},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT07310472","phase":"NA","title":"Administration of the Nasal Influenza Vaccine to Children in Daycare or at a Healthcare Facility","status":"RECRUITING","sponsor":"Turku University Hospital","startDate":"2025-10-27","conditions":"Influenza Vaccination","enrollment":6000},{"nctId":"NCT02597647","phase":"PHASE1","title":"Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-02","conditions":"Influenza","enrollment":17},{"nctId":"NCT07111078","phase":"PHASE1","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-27","conditions":"Influenza Prevention, Pandemic Influenza Prevention","enrollment":56},{"nctId":"NCT06074237","phase":"NA","title":"Improving Vaccine Counseling Skills Among Residents Using Educational Modules and Standardized Patient Encounters","status":"COMPLETED","sponsor":"Corewell Health East","startDate":"2024-04-25","conditions":"Vaccine Refusal, Vaccine-Preventable Diseases, Physician-Patient Relations","enrollment":112},{"nctId":"NCT07357467","phase":"","title":"Effect of Oral Supplement on Influenza Vaccine Long-term Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2026-03","conditions":"Influenza, Immunosenescence","enrollment":30},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT07357051","phase":"PHASE3","title":"Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza","status":"RECRUITING","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-11-07","conditions":"Respiratory Viral Infection","enrollment":177},{"nctId":"NCT07351500","phase":"PHASE3","title":"Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults","status":"NOT_YET_RECRUITING","sponsor":"Qingyuan Zhan","startDate":"2026-01-15","conditions":"Influenza","enrollment":496},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT07275060","phase":"PHASE4","title":"Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-14","conditions":"H5N1 Influenza, H5N1 Virus, Avian Influenza","enrollment":312}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1176,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trivalent Influenza Vaccines","Fluviral","Fluzone® TIV","2012/13 Seasonal Influenza Trivalent Inactivated Vaccine","Trivalent Inactivated Vaccine"],"phase":"marketed","status":"active","brandName":"TIV","genericName":"TIV","companyName":"Folia Biotech Inc.","companyId":"folia-biotech-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"TIV is a trivalent inactivated influenza vaccine that stimulates immune response against three strains of influenza virus. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}